Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • lzlgboy
    Junior Member
    • Jun 2011
    • 6

    DESeq can not detect significant DE genes.

    Dear all,
    I recently used DEseq to call DE genes and I have successfully run it for several dataset. However for the following dataset, I could not get any 'significant' DE gene with Padj < 0.05. Though, the within group variation between replicates are small and from the correlation between samples you can tell that CTR and Treated are obviously different. So my question is how could this happened? I have tried to figure out the problem but with no success.

    Here is my R command for the analysis:
    input file are attached behind. (ExperimentDesign.txt and RawCountTable.txt)
    =============================
    countTable.TBI.all = read.table("RawReadCount.txt",header=TRUE, row.names=1)
    designTable.TBI.all = read.table("ExperimentDesign.txt",header=TRUE, row.names=1)
    samples.CTR.vs.Treat = designTable.TBI.all$Condition == "CTR" | designTable.TBI.all$Condition =="Treat"
    countTable.CTR.vs.Treat = countTable.TBI.all[ , samples.CTR.vs.Treat]
    conditions.CTR.vs.Treat = designTable.TBI.all$Condition[samples.CTR.vs.Treat]
    conditions.CTR.vs.Treat = factor(conditions.CTR.vs.Treat)
    library(DESeq)
    CTR.vs.Treat.cds = newCountDataSet(countTable.CTR.vs.Treat, conditions.CTR.vs.Treat)
    CTR.vs.Treat.cds = estimateSizeFactors(CTR.vs.Treat.cds)
    CTR.vs.Treat.cds = estimateDispersions(CTR.vs.Treat.cds)
    CTR.vs.Treat.res = nbinomTest(CTR.vs.Treat.cds, "CTR", "Treat")
    ===================================================
    Attached Files
  • blancha
    Senior Member
    • May 2013
    • 367

    #2
    You just reversed the order of the treatment and control conditions.
    In your counts file, it's Treat1, Treat2, Treat3, CTR1, CTR2,
    In your conditions vector, it's CTR, CTR, Treat, Treat, Treat.
    It's actually reassuring that DESeq does not find any significant differences in gene expression with this input.

    > conditions.CTR.vs.Treat
    [1] CTR CTR Treat Treat Treat
    Levels: CTR Treat
    > head(countTable.CTR.vs.Treat)
    Treat1 Treat2 Treat3 CTR1 CTR2
    Mbp 255219 261306 295123 365033 415838
    Apoe 255618 333022 275713 31494 33771
    Gfap 135100 143838 143669 57978 62635
    Plp1 83787 92153 100662 165798 207643
    Fth1 97740 108155 113955 122369 117290
    Sparcl1 44654 43945 53549 72772 90997
    Last edited by blancha; 05-02-2014, 07:30 PM.

    Comment

    • lzlgboy
      Junior Member
      • Jun 2011
      • 6

      #3
      Thank you very much blancha~
      Works like a charm.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        Yesterday, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:10 AM
      0 responses
      8 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-09-2026, 10:04 AM
      0 responses
      39 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-08-2026, 10:08 AM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Working...